Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial.

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Grupo Español de Investigación en Neurooncología
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Grupo Español de Investigación en Neurooncología
ClinicalTrials.gov Identifier:
NCT01520870
First received: January 18, 2012
Last updated: August 1, 2014
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2015
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)